NanoViricides, Inc. (NNVCD) announced that it has raised $9,985,500 in a Registered Direct transaction. The common stock was sold at $3.50 per share, an approximate 26% discount to the market price ($4.76) of NNVCD at deal announcement. A series of 2,853,000 60-Month Warrants with an exercise price of $5.25 per share (10.29% premium) was issued to the investors in this transaction. Chardan Capital Markets and Midtown Partners acted as agents on the transaction. The transaction is expected to close by 09/13/2013.
Source: PlacementTracker
Posted on: September 11, 2013
NanoViricides, Inc. (NNVC) announced that it has raised $6,000,000 in a Convertible Unsecured Debentures transaction. The fixed conversion price of the Convertible Unsecured Debentures is $1.00 per share, an approximate 108.25% premium to the market price ($0.48) of NNVC at deal announcement. The Company shall pay interest of 8% per annum plus additional interest upon Closing and each anniversary of the Closing.
Source: PlacementTracker
Posted on: February 1, 2013
A veterinarian and a scientist have been raising millions in capital through Midtown Partners with registered direct offerings for their public biotech company NanoViricides (NNVC).
October 21, 2013
|
https://www.growthcapitalist.com/2013/10/hot-development-stage-biotech-accused-bad-behavior/
